RNAi Screen Indicates Widespread Biological Function for Human Natural Antisense Transcripts by Faghihi, Mohammad Ali et al.
RNAi Screen Indicates Widespread Biological Function
for Human Natural Antisense Transcripts
Mohammad Ali Faghihi
1, Jannet Kocerha
1¤, Farzaneh Modarresi
1,P a ¨r G. Engstro ¨m
3, Alistair M. Chalk
4,
Shaun P. Brothers
1, Eric Koesema
2, Georges St. Laurent III
5,6, Claes Wahlestedt
1,2*
1Department of Neuroscience, The Scripps Research Institute, Jupiter, Florida, United States of America, 2Department of Molecular Therapeutics, The Scripps Research
Institute, Jupiter, Florida, United States of America, 3Bioinformatics Institute, Hinxton, Cambridge, United Kingdom, 4National Centre for Adult Stem Cell Research, Eskitis
Institute for Cell and Molecular Therapies, Griffith University, Brisbane, Australia, 5Department of Molecular Biology, Cell Biology and Biochemistry, Brown University,
Providence, Rhode Island, United States of America, 6Immunovirology-Biogenisis Group, University of Antioquia, Medellin, Colombia
Abstract
Natural antisense transcripts represent a class of regulatory RNA molecules, which are characterized by their complementary
sequence to another RNA transcript. Extensive sequencing efforts suggest that natural antisense transcripts are prevalent
throughout the mammalian genome; however, their biological significance has not been well defined. We performed a loss-
of-function RNA interference (RNAi) screen, which targeted 797 evolutionary conserved antisense transcripts, and found
evidence for a regulatory role for a number of natural antisense transcripts. Specifically, we found that natural antisense
transcripts for CCPG1 and RAPGEF3 may functionally disrupt signaling pathways and corresponding biological phenotypes,
such as cell viability, either independently or in parallel with the corresponding sense transcript. Our results show that the
large-scale siRNA screen can be applied to evaluate natural antisense transcript modulation of fundamental cellular events.
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Introduction
Since the publication of the human genome, estimates of the
number of protein coding genes have remained remarkably stable.
In contrast, many surprises have come from the study of non-
protein-coding regions, challenging our understanding of mamma-
lian gene expression. Several high-throughput transcriptomic efforts
have demonstrated that a vast majority of the mammalian genome
is transcribed in vivo [1,2,3,4,5,6]. When measured as a percentage
of the total genome, non-protein-coding RNAs (ncRNAs) increase
consistently with developmental complexity of organisms across the
entire range of evolution [7]. In humans, ncRNAs comprise a
majority of the transcriptional output [8,9,10]. While this ncRNA
transcriptional output spans an impressive range, from the very
short to over 100 kb,most ofthe longertranscripts have received far
less experimental scrutiny compared to the small ncRNAs.
A sequencing-based transcriptomics effort, conducted by the
FANTOM3 consortium, confirmed and substantially extended the
previously existing reports [11,12,13,14] on the intriguing family
of long ncRNAs called natural antisense transcripts (NATs) [3,15].
Natural antisense transcripts are RNA molecules which are
transcribed from the opposite DNA strand to other transcripts
and overlap in part with sense RNA, promoter or regulatory
region. Both sense and antisense RNAs can encode proteins or be
non-protein-coding transcripts; however, the most prominent form
of antisense transcription in the mammalian genome is a non-
protein-coding antisense RNA partner of a protein-coding
transcript [15]. The antisense RNAs are often transcribed from
the same genomic locus as the sense transcript (cis-NATs), which
are focus of the current study. Sense and antisense RNAs can also
be transcribed from distinct genomic loci (trans-NATs). The
FANTOM3 collection includes at least 1,000 sense-antisense
transcript pairs, well conserved between mouse and human, and
many thousands of non-conserved pairs [16]. While some NATs
code for proteins, the majority lack conventional open reading
frames and therefore represent ncRNA [3]. The functions of long
ncRNA transcripts remain largely unknown [17]; nevertheless,
there are a few examples of long ncRNAs inducing rapid changes
in target gene expression during cellular responses to various forms
of stress (BACE1-AS [18]; HSR [19]; HIF1a-AS [20]; NRON
[21]). Stress in the nervous system may represent a focus of activity
for long ncRNAs, as the Allen Brain Atlas [22] revealed nearly one
thousand of these species localized to highly specific cell type
distributions in the mammalian brain [23]. Establishing the
connection of long ncRNAs to chronic stress and the onset of
neurodegeneration, we reported recently a NAT ncRNA that
functions to stabilize BACE1 mRNA and increase BACE1 gene
expression in vivo and in vitro [18]. Despite these and other
examples of functional NATs [24,25], it is still unclear whether
these reports represent exceptions or if they describe more
generalized regulatory architectures. Therefore, controversy still
surrounds the fundamental and largely unanswered question of
whether NATs participate in biologically significant information
processing and regulation of macromolecular machineries.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13177The combination of traditional cell culture techniques with
modern high-throughput genomics technology has enabled the
simultaneous interrogation of thousands of genes, facilitating the
functional analysis of complex biological processes [26,27]. Among
these, RNA interference (RNAi) can be used to expedite genome-
wide loss-of-function (LOF) screens in mammalian systems
[26,27,28,29]. Here, we exploited large-scale RNAi-mediated LOF
in cell-based assays to uncover the biological relevance of the NAT
family of RNAs. We report the construction of a comprehensive
siRNA library for functional analysis of NATs and confirm that seven
antisense transcripts impact the human cell viability phenotype.
Results
Design of siRNA library
The natural antisense transcripts examined in this study
comprise most of the nearly 1,000 sense-antisense transcript pairs,
conserved between human and mouse [16], originally identified
through the FANTOM3 transcriptomics effort. We used siSearch
[30] to rank all possible siRNAs targeting antisense transcripts of
the ,1000 NAT pairs. We then selected high scoring siRNAs and
tested these for specificity, using a wu-blast search against the
FANTOM3 transcriptome dataset. Those highly ranked, specific
siRNAs meeting selection criteria were selected for each NAT,
resulting in 2000 siRNA oligos targeting 797 NATs (172 coding
and 625 non-protein coding NATs). For coding-coding pairs, one
gene was arbitrarily assigned as NAT, although the other
transcript could also be considered the antisense transcript. In
most cases we tested three individual siRNA molecules for each
NAT to minimize non-specific results. Each siRNA was designed
to target only the non-overlapping part of the antisense RNA and
each siRNA was designed to have less binding affinity in the 5’ of
the negative strand [31]. The sequences for all siRNAs used in the
RNAi screen are listed in Table-S1.
Cell viability and proliferation screen
We used the Multidrop 384Titan Robot, designed to minimize
human experimental errors, to perform large-scale cell viability
screening on HEK293T cells in 384-well microtiter plates. Cells
were plated and co-transfected with pGL3 luciferase vector and
individual siRNAs and after 48 hours, luciferase activity was
measured as an indicator of cell viability (Table-S2). Each plate
included 8 wells of siRNA for pGL3 RNA as a positive control and
8 wells with no siRNA (mock transfection) as a negative control (a
detailed protocol description can be found in the methods section).
Figure 1 shows the distributions of luciferase intensity, normalized
and averaged over two replicate experiments, for NAT-targeted
siRNA and control measurements. Knockdown of luciferase (red
bars) consistently resulted in very low signal, confirming
transfection and knockdown efficiency in the system. Signals for
mock transfection (black bars) were on average somewhat lower
than signals from wells with experimental siRNA (green bars),
possibly due to toxicity of the transfection reagents in the absence
of siRNA. A ranked result list, including normalized signals for all
targeted transcripts, is given in Table-S3. The signals were
approximately normally distributed (Figure S1).
Validation of cell viability phenotype
Large-scale siRNA-mediated analysis of cell viability, like other
phenotypes, has the limitation of occasional inconsistency with
Figure 1. Histograms of normalized luciferase intensity for samples and controls. Intensities were normalized to the plate median (see
Methods) so that extreme positive values indicate an increase in viability relative to the median and extreme negative signals indicate a decrease in
viability.
doi:10.1371/journal.pone.0013177.g001
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selected 7 targets (Table 1) for validation by considering several
factors: the magnitude of the viability change as indicated by
normalized luciferase intensity, the number of siRNAs altering the
luciferase intensity in the same direction, and any documented
involvement of sense transcripts in cell survival and/or prolifer-
ation. For each of the 7 selected targets, we re-tested all 3 siRNAs,
even though not all of these siRNAs produced a strong change in
luciferase intensity in the primary screen. Luciferase intensity was
normalized by comparison with plate median in the primary
screen and by comparison with a control siRNA in the validation
screen (Figure-2). The difference in normalization approach is
necessitated by the difference in scale between the screens. The
validation results largely agree with the primary screen, indicating
that our primary screening results are generally reproducible.
Validated targets
We set strict criteria for target validation, requiring a significant
(P,0.05) change in luciferase intensity compared to control
siRNA for at least 2 out of 3 siRNAs. Three of the selected targets
are protein-coding genes that overlap other coding genes, whereas
the remaining four targets appear to be noncoding RNA (ncRNA).
We were able to validate 1 out of 3 protein-coding targets and 3
out of 4 ncRNA targets, for a combined success rate of 57%.
Specifically, we confirmed reduction in luciferase activity for
siRNAs against the noncoding NAT of cell cycle progression 1
(CCPG1) (Figure-2B) and for siRNAs targeted against the gene
ANKRD52, which encodes a protein of unknown function and
overlaps SLC39A5, a metal ion transporter gene (Figure-2A).
Further, we confirmed an increase in luciferase activity for siRNAs
against noncoding NATs of two genes: the nucleotidase gene
NT5C (Figure-2D) and the gene RAPGEF3 (Figure-2F). The latter
encodes a guanine-nucleotide-exchange factor (known as Epac1)
implicated in the regulation of cell proliferation [33]. Our failure
to validate three of the selected targets (ELL3-AS, DNM2 and
C12orf48; Figure-2 C, E, and G) can in part be explained by our
validation criteria being more stringent than our criteria for
selecting transcripts for validation. For example, DNM2 and
C12orf48 only showed a strong signal change for a single siRNA in
the primary screen (Table-S3).
Cell cycle and cell proliferation analysis
Change in cell viability could result from alterations in cell
cycle, global transcription, post-transcriptional regulation, or
translational efficacy. We measured cell viability with an
additional assay, using the Cyquant cell proliferation dye. For
these experiments, we focused on the NATs against CCPG1 and
RAPGEF3, because of the roles of these genes in regulation of cell
proliferation [33]. We observed that siRNA knockdown of CCPG1-
AS or CCPG1-sense significantly reduced cell proliferation detected
with the Cyquant assay (Figure-3A). Cells treated with siRNA to
RAPGEF3-AS also exhibited a decrease in cell proliferation as
measured with the Cyquant dye (Figure-3B). To narrow down the
source of the observed phenotype, HEK293T cells were
transfected with siRNAs against both sense and antisense
transcripts of CCPG1 and RAPGEF3 and alterations in cell cycle
progression were evaluated by fluorescence activated cell sorting
(FACS). We found that siRNA-mediated knockdown of CCPG1-AS
prompted ,20% increase in G1 phase and decreased cells in G2
by 25% (Figure-3C). A decrease of cells in G2 phase could indicate
impaired progression through the cycle and, therefore, explain the
observed cell viability reduction. siRNAs targeting RAPGEF3-AS
(Figure-3D) and other validated targets (data not shown) produced
no significant changes in cell cycle progression.
Regulatory relationship between sense and antisense
RNA molecules
To understand the pattern of antisense mediated regulation of
the sense transcript, we selected 3 validated targets with
demonstrated sense and antisense RNA expression in HEK293T
cells for further analysis using siRNA-mediated knockdown of the
antisense transcript (all siRNA and TaqMan primer sequences are
listed in Table- S1 and supplementary data-S1). Interestingly, for
all three targets we observed evidence for a discordant regulation,
where knockdown of the antisense transcript induces an
upregulation of the sense RNA. For ANKRD52, we only saw this
effect with one siRNA (Figure 4A), perhaps indicating that the
observed change in cell viability upon ANKRD52 knockdown is
unrelated to any natural antisense interactions it might have with
the overlapping SLC39A5 transcripts. Since ANKRD52 is a coding
gene of unknown function, this may point to a role of the encoded
protein in cell viability. For the two other targets, the effect was
more robust: knockdown of the noncoding antisense transcripts for
CCPG1 (Figure-4B) and RAPGEF3 (Figure-4C) led to a 30–80%
and 100–250% increase in their corresponding sense mRNA
expression, respectively. Additionally, we found that the expression
of the antisense transcripts could be downregulated when we
knocked down the sense transcripts (Figure-S2). These data suggest
Table 1. Selected targets from RNAi screen for validation studies.
Cell viability Acc # Sense ID Sense description Antisense ID Antisense description
Downregulation siRNA(1–3) AK056831 SLC39A5 zinc transporter ANKRD52 ankyrin repeat domain-
containing protein 52
Downregulation siRNA(4–6) AK093138 CCPG1 cell cycle progression 1 isoform 2 Noncoding
Downregulation siRNA(7–9) AK093233 ELL3 elongation factor RNAse II-like 3 Noncoding
Upregulation siRNA(10–12) AK094291 NT5C 5’,3’-nucleotidase, cytosolic Noncoding
Upregulation siRNA(13–15) AK097967 TMED1 interleukin 1 receptor-like 1 ligand
precursor
DNM2 dynamin 2 isoform 2
Upregulation siRNA(16–18) AL831948 RAPGEF3 RAP guanine-nucleotide-exchange
factor 3
Noncoding
Downregulation
siRNA(19–21)
BG105175 PMCH pro-melanin-concentrating hormone C12orf48 hypothetical protein LOC55010
doi:10.1371/journal.pone.0013177.t001
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RNA molecules; however, possible mechanisms why this coordi-
nate down-regulation might occur are not known.
Microarray analysis from RAPGEF-AS knockdown
experiments
To examine the global gene expression changes and signaling
pathways which could regulate NAT-mediated disruptions in cell
viability and proliferation, we carried out microarray gene
expression profiling on cells treated with siRNA to RAPGEF3-
AS. This approach identifies changes in transcript levels that are
directly or indirectly related to RAPGEF3-AS down-regulation or
RAPGEF3 up-regulation. We found that 22 protein-coding genes
out of 54,675 transcripts represented on the Affymetrix Human
U133 Plus 2.0 microarray were either down- or upregulated by
greater than 20-fold after siRNA treatment compared to mock
transfected controls (Table-S4). Indeed, several of the genes which
were found to be dysregulated in the microarray analysis are
associated with cell cycle regulatory events, including GDF15
(growth differentiation factor 15) [34], which was about 22.8 fold
decreased following RAPGEF3-AS knockdown, and UBE2L3
(ubiquitin-conjugating enzyme E2L 3) [35], which was upregu-
lated by 20.7 fold. A general schematic outlining the biological
pathways impacted by RAPGEF3-AS knockdown is illustrated in
Figure-S3.
Discussion
Long ncRNAs present a unique set of challenges for the study of
their molecular functions. Unlike microRNAs, whose well
described protein interaction pathways direct the processing and
utilization of their information content, long ncRNAs still have no
Figure 2. Validation of cell viability screen. A–G) targets were selected based on their Z-score and the number of effective siRNA for the same
target in the hit list (Table-S3). A schematic with the genomic organization for each NAT, drawn to scale, is indicated as an inset for each of the seven
prioritized targets. In the genomic schematics, antisense sequences are listed in red, sense sequences are listed in blue, and the arrows indicate
transcriptional direction. Boxes are indicating exons and lines are indicating introns. Four out of seven targets were validated as follows: siRNAs for
solute carrier family 39 (metal ion transporter), member 5- antisense (SLC39A5-AS), cell cycle progression 1- antisense (CCPG1-AS), 5’,3’-nucleotidase,
cytosolic- antisense (NT5C-AS), RAP guanine-nucleotide-exchange factor 3- antisense (RAPGEF3-AS) were able to reduce or increase luciferase activity
compared to a control siRNA, consistent with the original cell viability screen. siRNAs for elongation factor RNAse II-like 3- antisense (ELL3-AS),
interleukin 1 receptor-like 1 ligand precursor- antisense (TMED1-AS) and pro-melanin-concentrating hormone- antisense (PMCH-AS) were not able to
reproduce the same change in luciferase activity as compared to the original cell viability screen. There were 6 biological repeats for each treatment.
The data presented in graphs as a comparison with control siRNA-treated groups. We calculated the significance of each treatment as a p value
(***=P,0.0001, *=P,0.05, ns=P.0.05) and depicted in top of each graph.
doi:10.1371/journal.pone.0013177.g002
Figure 3. Cell cycle (FACS) and proliferation analysis. Knockdown of CCPG1-AS (A) and RAPGEF3-AS (B) decreases cell proliferation detected
with the Cyquant cell proliferation dye. C) CCPG1-AS siRNA, as compared to control siRNA, increases the number of cells in G1 phase and reduces the
number of cells in G2 phase as measured by FACS. D) siRNA silencing of RAPGEF3 sense transcript increases the number of cells in S phase and
reduces the number of cells in G2 phase. RAPGEF3-AS siRNA produces no significant impact on cell cycle detected by FACS analysis. We calculated
the significance of each treatment as a p value and depicted in top of each graph; (*=P,0.05).
doi:10.1371/journal.pone.0013177.g003
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persistent doubts about their relevance [36],[37]. Functional
validation studies indicate that antisense transcripts are not a
uniform group of regulatory RNAs but instead belong to multiple
categories with some common features [15]. Several functions
have been proposed for NATs including but not limited to
transcriptional interference [38], chromatin modifications [24]
and processing into small RNAs, which may function as
endogenous siRNAs [39,40,41]. Often kilobases in length, long
ncRNAs appear to contain far more information than could be
used efficiently by currently understood pathways, raising the
possibility that they could result from spurious transcription [42].
In this study we utilized a screening method to investigate the
functional significance of the NAT family of transcripts as a whole.
We show that some antisense transcripts are biologically functional
by providing evidence that, even in a single cell line, a number of
antisense transcripts impact the human cell viability phenotype.
Although we only selected seven NATs that scored highly in the
screen for follow-up studies, our validation success rate indicates
that the screening data likely contains many more examples of
NATs associated with cell viability.
Large scale functional screening provides an ideal strategy to
probe the significance of NATs [43]. Indeed, Willingham et al.
adopted this approach to uncover six ncRNAs essential for cell
viability, including NRON, a repressor of the transcription factor
NFAT [21]. Of note, the viability screen can identify a wide range
Figure 4. Antisense-mediated regulation of sense mRNA. A) siRNA knockdown of ankyrin repeat domain-containing protein 52 (ANKRD52),
the coding NAT for SLC39A5, did not alter the sense mRNA except with modest elevation with one siRNA in HEK293T cells B–C) Knockdown of the
noncoding NATs CCPG1-AS and RAPGEF3-AS caused statistically significant up-regulation of the sense mRNA. We calculated the significance of each
treatment as a p value and depicted in top of each graph; (**=P,0.001; ***=P,0.0001).
doi:10.1371/journal.pone.0013177.g004
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method for functional validation studies. Alteration in transcrip-
tion and translation efficiency as well as changes in cell
proliferation and cell cycle can be successfully monitored with a
cell viability phenotype. In addition to the original screen, we
employed multiple experimental approaches, such as luciferase
validation studies, FACS analysis, microarray and Cyquant cell
proliferation methods to examine the functional relevance of
selected NATs. For instance, we observed that knockdown of
CCPG1-AS exhibited a significant alteration in cell cycle progres-
sion by FACS analysis and that reduction of RAPGEF3-AS caused
a decrease in cell proliferation as measured with the Cyquant cell
proliferation assay. Furthermore, microarray analysis from cells
transfected with siRNA against RAPGEF3-AS identified several
genes that are affected by silencing of noncoding NATs. These
changes in gene expression might be explained by knockdown of
noncoding antisense transcript or it might be the consequence of
sense RAPGEF3 up-regulation. For example, UBE2L3 (ubiquitin-
conjugating enzyme E2L 3), responds robustly to RAPGEF3-AS
siRNA treatment. One established function of UBE2L3 is the
ubiquitination and subsequent degradation of p53, a well-
characterized tumor suppressor gene, which induces cell-cycle
arrest or apoptosis in response to cellular stress [35,44]. Decreased
p53 signaling could explain the observed change in luciferase
expression after treatment with siRNA to RAPGEF3-AS. Indeed,
RAPGEF3-AS knockdown reduced the transcript levels of p53
almost 4-fold in the microarray analysis. In this context, our data
not only reveals a biological role for these NATs, but uncovers a
rich texture of regulatory modulation of vital cellular signaling
landscapes.
Although we showed a biological role for a number of NATs in
the assay of cell viability and proliferation, this assay likely covers
only a small region of ‘‘phenotype space.’’ We propose that
thousands more examples of long ncRNA molecules may have
important functions, which cannot be monitored by our cell
viability assay. Additionally, human embryonic kidney cells
(HEK293T) cells might not express several of the NATs or their
corresponding sense partners. Generally, postnatal brain and
gonads are two tissues with relatively high expression of NATs;
however, antisense RNAs tend to have higher expression in
embryonic tissues. HEK293T cells express a relatively high
number of NATs, which might be related to their embryonic
source. One major limiting factor with siRNA library screening is
the transfection efficacy of targeted cells. Unlike HEK293T,
terminally differentiated cells including neurons and other
neuronal-like cell types do not typically exhibit optimal transfec-
tion efficiencies. Therefore, positive hits from our screening can be
selected for detailed functional studies in their relevant cell or
tissue types. The application of this NAT-focused siRNA library to
additional cellular pathways and phenotypic screens will likely
reveal further functional roles for this class of regulatory RNAs.
In some cases, both sense and antisense RNAs are protein
coding, making it difficult to assign one transcript as the regulatory
RNA transcript. For instance, in the SLC39A5/ANKRD52 pair,
both genes are protein coding and there appears to be only a very
small (,40 bp) overlap of the 3’-UTRs of the two transcripts. It is
worth nothing that about half of the human or mouse genes
exhibit alternative polyadenylation among their transcripts [45].
As a result, each defined 3’ end of a transcript has, on average, 1.3
start sites; conversely, each 5’ end has an average 1.8
corresponding 3’ ends [4,46]. Therefore, this 40 bp overlapping
region could very well expand to a few hundred base pairs of
complementary nucleotides. Nevertheless, for coding NATs, there
is always a chance that the encoded protein, and not regulatory
non-protein-coding properties of the transcripts, might mediate
the observed effect on cell viability.
Evolutionary conservation can be highly effective for identifying
functional elements in genomes [47]. Thus, we selected the
transcripts for our current study from the list of one thousand
NATs identified in the FANTOM3 project as conserved between
human and mice [16]. However, lack of conservation does not
necessarily indicate lack of function [48]. The non-conserved
sequences might relate to the emergence of human-specific brain
features [49]. Reports of functional primate- or human-specific
NATs [50,51,52,53] suggest that many non-conserved NATs may
indeed play functional roles in the nervous system [23]. The
distinction between conserved and non-conserved transcripts is not
always clear-cut, as exemplified by the human accelerated region 1
(HAR1). The HAR1 genomic region exhibits a high level of
conservation from chicken to chimpanzee, but has changed
rapidly in the human lineage. HAR1 gives rise to multiple
antisense-overlapping ncRNAs, one of which is specifically
expressed in Cajal-Retzius neurons of the developing neocortex
of humans and other primates [49]. Since the NAT class of long
RNAs comprises over 5000 known members in humans, most of
which are ncRNAs [54], and estimates of total long ncRNA
species ranges to over 20,000 transcripts [23], we can expect a
widespread potential for human specific regulatory complexity
from these ncRNAs in tissues such as the nervous system. Overall,
our results now suggest that the conserved members of the NAT
family have function. They represent a large reservoir of
information potentially useful to regulate cellular processes, and
may add yet another dimension to our growing understanding of
the functional complexity of mammalian gene loci.
Methods
siRNA library
We constructed an siRNA library, containing 2000 siRNA
targeting 797 conserved NAT (1-3 siRNA to each). Each siRNA
was designed to target the antisense transcript but not the
corresponding sense transcript partner, using Karolinska Institute
siRNA designing tools [30]. List of siRNA oligos, including siRNA
design scoring and the siRNA targets are in supplementary table
S1, energies are calculated as previously described [30].
Luciferase assay
Using Multidrop 384Titan, 50 ng of pGL3 vector (luciferase
vector with SV40 promoter), 50 nM of siRNA and transfection
reagents (Lipofectamine 2000 0.2% and OptiMEM) were plated in
384 well plates. Equal numbers of HEK-293T cells (5,000/well)
were added to each well and incubated at 37uC for 48 hours.
Bright-Glu luciferase reagent was added to each well and
incubated at room temperature for 5 minutes. Luciferase activity,
as a marker of cell viability, was measured by Analyst GT
Multimode Reader.
Statistical analysis
In analyzing the data, we made use of the R/Bioconductor
package cellHTS2 [55]. Spatial effects were identified by plotting
the intensities by their position on the plates and putative artifacts
were masked out (Table-S2). Intensities were centered at 0 by
subtracting plate median and scaled by dividing by plate median
absolute deviation (MAD). Only experimental siRNA (non-
control) wells were used to compute median and MAD. Finally,
normalized signals were averaged over the two replicate
experiments.
Natural Antisense Transcripts
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and 3–6 technical repeats. The data presented in graphs as a
comparison with control-treated groups, after post-hoc test of
treatment factor using main effect in one or two-way analysis of
variance (ANOVA). We calculated the significance of each
treatment as a p value and depicted in each graph, (p,0.05) was
considered significant.
Validation of cell viability assay
Using Multidrop 384Titan, 50 ng of pGL3 vector (luciferase
vector with SV40 promoter), 20 nM of siRNA (three siRNA per
target n=24) and transfection reagents (Lipofectamine 2000 0.2%
and OptiMEM, Invitrogen, CA) were plated in 96 well plates.
Equal number of cells (10,000 per well) were added to each well
and incubated at 37uC for 48 hours. Bright-Glo luciferase reagent
(Promega, Madison, WI) was added to each well and incubated at
room temperature for 5 minutes. Luciferase activity, as a marker
of cell viability, was measured by Analyst GT Multimode Reader
(Molecular Devices, Sunnyvale, CA) and plotted against control
siRNA.
Cell culture, siRNA transfection and RNA isolation
HEK-293T cells were cultured in MEM plus 10% FBS. Cells in
the logarithmic growth phase were transfected with 20 nM of
siRNA using 0.2% Lipofectamine 2000 according to manufactur-
er’s instructions (Invitrogen, Carlsbad, CA). Cells were incubated
for 48 hours prior to RNA isolation. Total RNA was extracted
using RNeasy mini kit (QIAGEN, Valencia, CA). All samples were
treated with RNAse-free DNase (QIAGEN, Valencia, CA) for 15
minutes as described in the manufacturer’s protocol. RNA
concentrations were measured using the NanoDropH ND-1000
UV-Vis Spectrophotometer. Equal amounts of RNA were reverse
transcribed using TaqMan reverse transcription reagents (Applied
Biosystems, Foster City, CA) according to the manufacturer’s
protocol.
Microarray analysis
HEK293T cells were treated with 20 nM of control siRNA
(Ambion) or siRNA to RAPGEF3-AS. After 48 hours post-
t r a n s f e c t i o n ,R N Aw a si s o l a t e df r o mt h ec e l l sa so u t l i n e din the cell
culture section above and pooled from 6 replicates each for control
and RAPGEF3-AS siRNA treated samples. Double-stranded cDNA
was prepared from 1 mgo ft o t a lR N Au s i n gt h eA f f y m e t r i xc D N A
synthesis kit and then in vitro transcribed using an IVT labeling kit
(Affymetrix), with the cRNA product purified using a GeneChip
Sample Cleanup Module (Affymetrix). 20 mg biotin-labeled cRNA
was fragmented and hybridized to Affymetrix Human U133 Plus 2.0
microarray overnight in the Affy 640 hybridization oven with a speed
of 60 rpm for 16 hr. Microarrays were washed and stained using the
Affymetrix Fluidics Station FS400. GeneChip arrays were scanned
using a GeneChip Scanner 3000 (Affymetrix). The probe set
intensities were quantified using the GeneChip Operating Software
(GCOS) and analyzed with GCRMA normalization using Array
Assist Software (Stratagene, La Jolla, CA). All hybridized chips met
standard quality control criteria, and mean fluorescence values of
each array were scaled to a mean intensity of 500. Microarray data is
MIAME compliant and the raw data has been deposited in a
MIAME compliant database. We expect to receive accession
numbers whilst the manuscript is under review.
Real-Time PCR
Real-Time PCR (RT-PCR) was carried out with the GeneAmp
7900 (Applied Biosystems, Foster City, CA). The PCR reactions
contained 20–40 ng cDNA, Universal Mastermix (Applied
Biosystems, Foster City, CA), 300 nM of forward and reverse
primers, and 200 nM of probe in a final reaction volume of 15 ml.
The primers and probe were designed using File-Builder software
(Applied Biosystems, Foster City, CA). The PCR conditions were
as follows: 50 C for 2 min then 95 C for 10 min then 40 cycles of
95 C for 15 s and 60 C for 1 min. The results are based on cycle
threshold (Ct) values. Differences between the Ct values for
experimental and reference genes (18S rRNA) were calculated as
DDCt.
Cyquant cell proliferation assay
HEK293T cells were seeded with either 200 cells/well or 1000
cells/well in a 96-well plate and reverse transfected with 20 nM of
siRNA for 48 hours. After 48 hours, the media was removed and
100 mls of a diluted Cyquant solution was added to each well.
Each plate was then incubated at 37u for one hour and then read
on the Fluoroskan Ascent FL from Thermo Corporation.
Cell cycle analysis
Selected viability-related NATs were subjected to cell cycle
analysis. We knocked down NATs using three siRNA for each
target, and we used a control negative siRNA (triplicate for each
treatment) to examine the effects of selected NATs on the cell
cycle. At 48 hours post transfection, we prepared the cells for flow
cytometry as follows: cells were washed with PBS, trypsinized and
centrifuged at 1,000 rpm for 10 minutes. Then the cells were
washed again with PBS before being fixed with 70% ethanol at
22uC overnight. The next day the cells were centrifuged, washed
with PBS and re-suspended in 38 mM sodium citrate, 69 mM
propidium iodide and 19 mg/ml RNAse A for flow cytometry
analysis. Results were analyzed using FlowJo analysis software.
Supporting Information
Table S1 Library siRNA sequences. Sequences for all siRNAs
used in the RNAi screen are listed.
Found at: doi:10.1371/journal.pone.0013177.s001 (0.62 MB
XLS)
Table S2 Raw data from the RNAi screen. Luciferase intensity
prior to normalization for each well on the microtiter plates.
Found at: doi:10.1371/journal.pone.0013177.s002 (0.30 MB
XLS)
Table S3 Normalized data from the RNAi screen. Normalized
luciferase intensities are listed for each target along with some
metrics used for ranking the targets. See legend on the second
sheet of the Excel file for details.
Found at: doi:10.1371/journal.pone.0013177.s003 (0.25 MB
XLS)
Table S4 Microarray data. The mean fluorescence values for all
transcripts altered greater than 20-fold after siRNA treatment
against RAPGEF3 on the Affymetrix array is indicated.
Found at: doi:10.1371/journal.pone.0013177.s004 (0.02 MB
XLS)
Figure S1 Quantile-quantile plot of normalized luciferase
signals, demonstrating that the signals are approximately normally
distributed. Signals from control wells are not shown.
Found at: doi:10.1371/journal.pone.0013177.s005 (1.49 MB TIF)
Figure S2 Knockdown of sense transcripts. Two to three
different siRNAs were used to knockdown the sense transcripts
for three of the validated NAT targets. Expression of the sense and
NAT mRNA was evaluated by real-time PCR. We calculated the
Natural Antisense Transcripts
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13177significance of each treatment as a p value and depicted on top of
each graph; (**=P,0.001; ***=P,0.0001).
Found at: doi:10.1371/journal.pone.0013177.s006 (4.97 MB TIF)
Figure S3 Microarray analysis RNA was extracted from
HEK293T cells transfected with siRNA to RAPGEF3-AS and
analyzed by Affymetrix array for global gene expression changes.
Out of 54,675 transcripts represented on the microarray, 22 genes
were altered by greater than 20 fold with siRNA knockdown. The
major biological pathways impacted by silencing of RAPGEF3-
AS, including cell survival and proliferation, are represented in the
schematic generated with Pathway Studio software [56].
Found at: doi:10.1371/journal.pone.0013177.s007 (8.92 MB TIF)
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